These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35625189)

  • 1. German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant
    Manzke J; Stauf R; Neumann B; Molitor E; Hischebeth G; Simon M; Jantsch J; Rödel J; Becker SL; Halfmann A; Wichelhaus TA; Hogardt M; Serr A; Hess C; Wendel AF; Siegel E; Rohde H; Zimmermann S; Steinmann J
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021.
    Wise MG; Karlowsky JA; Hackel MA; Harti MA; Ntshole BME; Njagua EN; Oladele R; Samuel C; Khan S; Wadula J; Lowman W; Lembede BW; Sahm DF
    J Glob Antimicrob Resist; 2023 Dec; 35():93-100. PubMed ID: 37709139
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
    Tuan Soh TS; Salvinder S; Chen VSY
    Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
    Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
    Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
    Stone GG; Seifert H; Nord CE
    Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020.
    Karlowsky JA; Bouchillon SK; Benaouda A; Soraa N; Zerouali K; Mohamed N; Alami T; Sahm DF
    J Glob Antimicrob Resist; 2022 Sep; 30():23-30. PubMed ID: 35447385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
    Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017.
    Stone GG; Ponce-de-Leon A
    J Antimicrob Chemother; 2020 Jul; 75(7):1859-1873. PubMed ID: 32277820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
    J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases.
    Abouelhassan Y; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2023 Aug; 78(8):1843-1847. PubMed ID: 37357368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.